Gordon Medical Research Center is dedicated to reversing the rising tide of chronic illness.
Today, diseases are defined by their symptoms rather than their cause. Leading to therapies that are ineffective for treatment reversal.
Finding and treating the causes before the disease takes root in the organs increases the possibility of preventing disease progression!
Detecting early biomarkers before disease symptoms manifest will lead to a new understanding of the cause and course of disease
Metabolomics combined with genomics and exposomics will reveal a new picture of how the bodies self-healing capacities break down and how they can be restored.
We are building partnerships between leading academic researchers and integrative doctors to discover a new model for preventative and regenerative medicine.
GMRC is a California non-profit corporation and active US 501c3.
Board of Directors
Eric D. Gordon, MD
Eric D. Gordon, MD, President of GMRC, is the founder and owner of Gordon Medical Associates (GMA), a private medical practice specializing in chronic illness. Doctor Gordon has close familial ties and personal relationships with individuals with poorly defined chronic illnesses, as well as his long term service to patients with these illnesses (30+ years). In addition to seeing patients in his practice, Dr. Gordon organized and served as medical advisor and moderator for a series of medical symposia in Northern California, from 2007-2009. These intensive five-day meetings brought together extraordinary faculties consisting of approximately 30 leading international academic medical researchers and cutting-edge clinicians, respectively focusing on CFS, Lyme, autoimmune diseases and autism. The collaboration of an innovative medical practice with a university research center has been his lifelong dream. Combining forces with Dr. Robert Naviaux and his research into metabolomics, mitochondrial function, and chronic inflammatory disease is now bringing this dream to life.
Wayne Anderson, ND
Wayne Anderson, ND is a practicing doctor at Gordon Medical Associates, with more than 25 years of experience treating poorly understood illness. For two decades, Dr. Anderson practiced in a busy community-based family medical center, treating individuals and families from birth to old age. he has been at GMA since 2002, working with the complex patients of that practice. In addition to his clinical practice, Dr. Anderson has maintained his initial focus on teaching. For over 20 years he taught medical students at Touro Osteopathic Medical School, and supervised residents from Sutter Hospital and interns from the Physician Assistant programs in the clinic setting. He is also a popular speaker on the topics of Lyme disease and neurotoxin illness.
Tom Eames, Secretary of GMRC
Tom retired after being a widely recognized technical leader in the Telecommunications industry with over 25 years of experience in systems architecture, design and development. He was a founder of Next Level Communications in 1994 where he led the architecture and the system development of the Broadband Unified Access Platform. He was previously a founding member of Optilink in 1987, where he was the chief architect of a next-generation Digital Loop Carrier System (NGDLC), that captured a leading share of the regional bell operating companies local loop electronic market place. He was responsible for the architecture as well as managing the system engineering development. Mr. Eames has been responsible for architecture and design of several earlier Telecommunications engineering development programs including Private Branch Exchange (PBX) programs at Digital Telephone Systems, Harris Inc. prior to Optilink. Mr. Eames has a Bachelor of Science degree (BSCS) in Computer Science from California State University and holder of numerous Telecommunication system patents.
Mark Blatt, MD, MBA,Chief Financial Officer of GMRC
Mark has 35+ years as an MD. Dr. Blatt left the practice of clinical medicine after 17 years to pursue his dream of bringing affordable, convenient, safe, and effective healthcare to patients. In 2000, after getting his MBA in Finance at Yale, Dr. Blatt joined Intel Corporation. He started as Manager Health Strategies, and last served as Worldwide Medical Director for five years, until he retired in 2015. He continues to be passionate about the adaptation of remote care and other technological innovations that will improve health care delivery and safety. His end-goal remains ensuring affordable quality healthcare for all.
Advisors
Robert Naviaux, MD PhD
Dr. Naviaux is a Professor of Genetics, in the Departments of Medicine, Pediatrics, and Pathology. He directs a core laboratory for metabolomics at UCSD. He is the co-founder and a former president of the Mitochondrial Medicine Society (MMS), and a founding associate editor of the journal Mitochondrion. He is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome---the oldest Mendelian form of mitochondrial disease---and the developer of the first DNA test to diagnose it. Dr. Naviaux's lab has developed a number of advanced technologies like biocavity laser spectroscopy and mtDNA mutation detection by mass spectrometry.
He is a Salk-trained virologist, and molecular and cell biologist, the inventor of the popular pCL retroviral gene transfer vectors, and was trained at NIH in tumor immunology and natural killer cell biology. He studied biochemistry at Georg-August University in Göttingen, Germany. He has been the PI for over 20 IRB-approved human subjects protocols at UCSD since 1995. In 2010, Dr. Naviaux was a member of the Cal-Echoes oceanographic expedition to collect environmental and ecosystem data along the California coast. His work in ecosystem dynamics has guided new work in microbiome ecology and metabolism in autism spectrum disorders. In 2011, he received a Trailblazer Award from Autism Speaks. His 2013 paper reporting preclinical studies on the role of purinergic signaling and the cell danger response in autism was ranked the #1 most-viewed report of 2013 on the Simons Foundation autism web site. He was the director of SAT1 trial, the first FDA-approved clinical trial to study the safety and test the effects of suramin on behavior and language in children with autism.
Our Partners
Thank you to our generous sponsors
Tonye Marie Casteneda, Tom Eames, Laura Fielder, Saylor Fielder, Raina Fielder, Michelle Phillips, Kent Heckenlively, Stephen Baker, Melissa Kaplan, Edward Phillips, Margaret Phillips, Jill Harrison, Tina Smith, Mark Camenzind, Susanna Agardy, Brent Handel, Susan Friedl, Olivia Glass, B.E. Lyn Cushing, Erica Freeman, Jiki Bertsch-Betts, Sally Scarlett, Susan Murphy, Catherine Thomson, Edward Montgomery, Anthony Ross, Stephen Greer, Arvey I Rogers, M.D., Eric Gordon and Gordon Medical Associates, Vanguard Charitable
And all those who donate anonymously!